作者
Juliet Carmichael,Ines Figueiredo,Bora Gürel,Nick Beije,Wei Yuan,Jan Rekowski,George Seed,Suzanne Carreira,Claudia Bertan,Maria de los Dolores Fenor de la Maza,Khobe Chandran,Antje Neeb,Jon Welti,Lewis Gallagher,Denisa Bogdan,Mateus Crespo,Ruth Riisnaes,Ana Ferreira,Susana Miranda,Jinqiu Lu,Michael M. Shen,Emma Hall,Núria Porta,Daniel Westaby,Christina Guo,Rafael Grochot,Christopher J. Lord,Joaquín Mateo,Adam Sharp,Johann S. de Bono
摘要
BACKGROUND. Clinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports on RNASEH2B protein loss in advanced prostate cancer and its association with RB1 protein loss, clinical outcome and clonal dynamics during treatment with PARP inhibition in a prospective clinical trial.
西红柿炒番茄
坚强的广山
zho
eve
rosalieshi
kk
嗯哼
薰硝壤
顺心蜜粉
yznfly
寻道图强
兔子
HEIKU
shinysparrow
yzlsci
saeda
sswbzh
AireenBeryl531
priss111
tianzml0
皖公网安备34019202002308
